DNA and Gene Cloning Services Market Expands with Growing Focus on Complex Gene Constructs and Scalable Gene Synthesis Platforms

InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global DNA and Gene Cloning Services Market by Type of Service Offered (Custom Cloning, Sub-cloning, Gene Synthesis, and Others), Type of Gene (Complex Gene, Standard Gene, and Others), End-User Industry (Pharmaceutical, Academic and R&D, and Biotechnology Companies, and Others)- Market Outlook and Industry Analysis 2034"

The DNA and Gene Cloning Services Market Size is valued at USD 2.6 Bn in 2024 and is predicted to reach USD 11.7 Bn by the year 2034 at a 16.4 % CAGR during the forecast period for 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1357

The significant market companies are Bio-Techne, Curia, Eurofins, GenScript, MedGenome, Integrated DNA Technologies, Sino Biological, Syngene, Twist Bioscience, Thermo Fisher Scientific Inc., Charles River Laboratories, Eurofins Scientific, GenScript, Merck KGaA, Takara Bio Inc., Lonza, Sartorius AG, Creative Biogene, Cellecta, Inc., Synbio Technologies, TransGen Biotech Co., Ltd., Dobuss (Canvax), Azenta US, Inc., Macrogen, Inc., Codex DNA, Inc., Bio-Rad, and other key players.

Key Developments in the Market
• In Jan 2021, Codex DNA and Pfizer signed an early access collaboration and licencing agreement, which will allow Pfizer to use CodexDNA's novel enzymatic DNA synthesis technology in its research and development of mRNA-based vaccines and biotherapies. Codex DNA will be responsible for further developing the technology.
• In May 2020, GenScript just launched a GMP single-strand and double-strand DNA service to aid in the growth of gene and cell therapies. The announcement highlights GenScript's commitment to assisting entire non-viral cell therapy development through the IND-enabling and clinical stages.
• In Dec 2020, Thermo Fisher increased its plasmid DNA manufacturing clinical and commercial capabilities. Commercialization of plasmid-based drugs and vaccines will be accelerated by the opening of a new cGMP facility in Carlsbad, California. The facility will also be able to generate large amounts of plasmid DNA, which is a crucial component of drugs used in DNA treatments. This growth builds on the business's ongoing commitment to providing cell and gene therapy services.
• In May 2020, Takara Bio announced a collaboration with AGC Biologics. The businesses will collaborate on a prophylactic DNA vaccine against COVID-19, with AGC Biologics manufacturing the plasmid DNA intermediate for the vaccine.

Gene synthesis and cloning serve as foundational techniques across a wide range of scientific and biotechnological applications. Commonly utilized DNA amplification methods, such as subcloning and polymerase chain reaction (PCR), are integral to genetic cloning processes. Recombinant DNA technology-also referred to as DNA cloning-involves the integration of genetic material from two distinct sources into a single DNA molecule, which is subsequently introduced into a host organism to produce genetically modified progeny.

This technology is extensively applied in areas such as protein expression, gene function analysis, and the development of gene-based therapies. The standard workflow includes isolating DNA from a source organism, identifying the target gene, and replicating it through molecular cloning techniques. Key procedural steps involve plasmid DNA extraction, enzymatic digestion using restriction enzymes, and the insertion of recombinant DNA into a host cell to enable replication. PCR plays a crucial role in amplifying DNA sequences throughout this process. In the context of genetic engineering, gene cloning refers to the generation of synthetic gene copies for use in research, diagnostics, and therapeutic development.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03

Gene cloning can be performed through two principal methodologies: in vivo and in vitro. Numerous human genes have been successfully cloned into microbial systems such as Escherichia coli and yeast, facilitating the large-scale in vitro production of human proteins. Currently, over one hundred therapeutic drugs are manufactured using genetically modified cells-including E. coli, yeast, and mammalian cells-engineered with human gene sequences. Gene cloning has emerged as a transformative tool in biotechnology, significantly contributing to advancements in human healthcare by enabling more effective treatments for chronic conditions and subsequently improving life expectancy. In the agricultural sector, gene cloning continues to enhance crop quality and nutritional content.

The global market for DNA and gene cloning services is expected to witness sustained growth in the coming years. This upward trajectory is driven by the increasing adoption of gene therapies and ongoing innovations in DNA cloning technologies. Rising investment in research and development, along with growing demand for personalized medicine, further accelerates market expansion. Additionally, the sector benefits from robust funding support, continuous technological improvements, and an expanding number of companies entering the market.

Despite these favorable developments, the gene synthesis and cloning market faces certain challenges, including a shortage of skilled professionals and protracted regulatory approval timelines. Nevertheless, ongoing technological advancements, strategic collaborations, and mergers and acquisitions in the biomedical and healthcare industries are poised to create substantial growth opportunities. With strong capital investment and increasing integration of gene cloning technologies into life sciences research-particularly in North America-the market is positioned for continued development.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1357

Market Segmentation:
Global DNA and Gene Cloning Services Market, by Type of Service Offered, 2023-2031 (Value US$ Mn)
• Custom Cloning
• Gene Synthesis
• Sub-cloning
• Others
Global DNA and Gene Cloning Services Market, by Type of Gene, 2023-2031 (Value US$ Mn)
• Complex Gene
• Standard Gene
• Others
Global DNA and Gene Cloning Services Market, by End-User Industry, 2023-2031 (Value US$ Mn)
• Academic and R&D
• Pharmaceutical and Biotechnology Companies
• Others
Global DNA and Gene Cloning Services Market, by Region, 2023-2031 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America DNA and Gene Cloning Services Market, by Country, 2023-2031 (Value US$ Mn)
• U.S.
• Canada
Europe DNA and Gene Cloning Services Market, by Country, 2023-2031 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific DNA and Gene Cloning Services Market, by Country, 2023-2031 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America DNA and Gene Cloning Services Market, by Country, 2023-2031 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa DNA and Gene Cloning Services Market, by Country, 2023-2031 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Read Overview Report- https://www.insightaceanalytic.com/report/global-dna-and-gene-cloning-services-market-/1357

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.